Document is current
Any future updates will be listed below
-
Authors
Verhoeven, David
Sponseller, Brett A.
Crowe, James E. Jr.
Bangaru, Sandhya
Webby, Richard J.
Lee, Brian M.
-
Funding
Funding for this research was provided by:
Merck
- License Information
-
More Information
Article History
Received: 25 August 2024
Accepted: 25 November 2024
First Online: 19 December 2024
Competing interests
: The vaccine used in this study is based on a veterinary vaccine (FluAvert) manufactured by Merck Sharp & Dohme LLC. However, Merck was not involved in the planning or execution of this study. D.V. and B.S. have a patent granted for the use of A/equine/Kentucky/91 for use as a universal influenza vaccine and are developing it for use for our company Syntherna. J.E.C. has served as a consultant for Luna Labs USA, Merck Sharp & Dohme Corporation, Emergent Biosolutions, a former member of the Scientific Advisory Boards of Gigagen (Grifols), of Meissa Vaccines, and BTG International, is founder of IDBiologics and receives royalties from UpToDate. The laboratory of J.E.C. received unrelated sponsored research agreements from AstraZeneca, Takeda Vaccines, and IDBiologics during the conduct of the study.
